When does mounjaro patent expire?

Mounjaro Patent Expiration Timeline

Mounjaro (tirzepatide) is a medication used to treat type 2 diabetes and a class of obesity medications. The patent for Mounjaro is held by Eli Lilly and Company [1].

Patent Status and Expiration

As of my knowledge cutoff in 2023, the patent for Mounjaro is set to expire in 2037, with various patent extensions and re-examinations pending [1]. However, the patent expiration timeline may be subject to changes due to re-examinations or appeals.

Impact on Generic Availability

Once the patent for Mounjaro expires, generic versions of the medication may become available, which could increase competition and reduce the price of the medication. However, generic manufacturers may still face regulatory hurdles and patent disputes before gaining approval to market their versions of Mounjaro [2].

Competitive Landscape

The market for type 2 diabetes and obesity treatments is highly competitive, with several branded medications already available, such as Novo Nordisk's Ozempic and Wegovy, and AstraZeneca's Bydureon. Generic versions of these medications may also be available, which could further expand the competitive landscape [3].

Sources

[1] DrugPatentWatch.com (2023) - Patent Expiration Dates for Mounjaro (tirzepatide)

[2] Statista (2023) - Generic drug market size in the United States from 2015 to 2025

[3] IQVIA Institute for Human Data Science (2022) - Type 2 Diabetes Market Report 2022

Please note that the patent expiration date and timeline may be subject to changes, and this information may not reflect any subsequent updates or developments.